Maraviroc belongs to a new class of anti-HIV drugs named CCR5 antagonists, which block HIV entry into cells. It has proven potent efficacy in treatment-experienced patients with multiple drug failure. Its favourable toxicity profile makes the drug attractive for consideration in other clinical scenarios, including patients with earlier stages of disease, cardiovascular risk and viral hepatitis coinfection. Because of its unique mechanism of action-blocking viral entry, studies in patients with primary HIV infection and in the context of preexposure and postexposure prophylaxis are particularly warranted. However, given its exclusive activity against CCR5 tropic strains, viral tropism testing is mandatory before using CCR5 antagonists in the clinic. Efforts to improve the reliability of viral tropism assessment using genotypic tests are underway, and it is likely that these tools will soon replace phenotypic assays, which are more expensive, difficult to perform and take a long time. © 2008 Wolters Kluwer Health Lippincott Williams & Wilkins.

Soriano, V., Geretti, A., Perno, C.f., Fatkenheuer, G., Pillay, D., Reynes, J., et al. (2008). Optimal use of maraviroc in clinical practice. AIDS, 22(17), 2231-2240 [10.1097/QAD.0b013e3283136d95].

Optimal use of maraviroc in clinical practice

PERNO, CARLO FEDERICO;
2008-01-01

Abstract

Maraviroc belongs to a new class of anti-HIV drugs named CCR5 antagonists, which block HIV entry into cells. It has proven potent efficacy in treatment-experienced patients with multiple drug failure. Its favourable toxicity profile makes the drug attractive for consideration in other clinical scenarios, including patients with earlier stages of disease, cardiovascular risk and viral hepatitis coinfection. Because of its unique mechanism of action-blocking viral entry, studies in patients with primary HIV infection and in the context of preexposure and postexposure prophylaxis are particularly warranted. However, given its exclusive activity against CCR5 tropic strains, viral tropism testing is mandatory before using CCR5 antagonists in the clinic. Efforts to improve the reliability of viral tropism assessment using genotypic tests are underway, and it is likely that these tools will soon replace phenotypic assays, which are more expensive, difficult to perform and take a long time. © 2008 Wolters Kluwer Health Lippincott Williams & Wilkins.
2008
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA
English
Con Impact Factor ISI
Chemokine (C-C motif) receptor 5 antagonists; HIV; Maraviroc; Tropism
Soriano, V., Geretti, A., Perno, C.f., Fatkenheuer, G., Pillay, D., Reynes, J., et al. (2008). Optimal use of maraviroc in clinical practice. AIDS, 22(17), 2231-2240 [10.1097/QAD.0b013e3283136d95].
Soriano, V; Geretti, A; Perno, Cf; Fatkenheuer, G; Pillay, D; Reynes, J; Tambussi, G; Calvez, V; Alcami, J; Rockstroh, J
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons Creative Commons

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/47728
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 29
social impact